Cholesterol and Sphingolipids in Non-Alcoholic fatty liver disease.

Similar documents
NIH Public Access Author Manuscript J Hepatol. Author manuscript; available in PMC 2014 October 01.

ON LINE DATA SUPPLEMENT

Review. Yaron Ilan. Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel

HEPATOCARCINOGENESIS AND CERAMIDE/CHOLESTEROL METABOLISM. Fernández-Checa 1,2

NASH Bench to Bedside

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

Sphingolipid de novo synthesis: its relevance to metabolic diseases and cell polarity

Improving Access to Quality Medical Care Webinar Series

Fat Metabolism, Insulin and MTHFR

Gene Polymorphisms and Carbohydrate Diets. James M. Ntambi Ph.D

Mechanisms and clinical implications of hepatocyte lipoapoptosis

SUPPLEMENTARY INFORMATION

Nutrition and Age-Associated Inflammation :Role of Nutritional Intervention Simin Nikbin Meydani, DVM, PhD.

Is there a common mechanism of DILI, do we need to know?

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

Alcoholic hepatitis is a drug-induced disorder

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

NONALCOHOLIC FATTY LIVER DISEASE

Steatotic liver disease

FOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB

Supplementary Figure 1. DNA methylation of the adiponectin promoter R1, Pparg2, and Tnfa promoter in adipocytes is not affected by obesity.

Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression

Disclosures. Outline. Extracellular Vesicles in Fatty Liver Disease. From Contributors to disease pathogenesis to novel biomarkers

METABOLIC SYNDROME AND HCV: FROM HCV

Conflicts of Interest in the last 12 months

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

How Will New Therapies Affect HCC Development?

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease. Ekihiro Seki, M.D.,Ph.D. University of California San Diego

Therapeutic targets and the management of NASH

The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis

Disclosures. Outline. Nothing to disclose. Dysbiosis and the gut barrier. Endotoxemia and the liver. Impact of products of bacterial metabolism

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

Revisiting the metabolic syndrome and paving the way for micrornas in non-alcoholic fatty liver disease

Metabolic defects underlying dyslipidemia in abdominal obesity

Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

Liver Pathology in the 0bese

Review. Mitochondrial cholesterol in health and disease

research article Tris-HCl, ph 7.5) with culture medium to a concentration of U/ml as described previously (37). Some cultures were pretreated

MITOCHONDRIAL OXIDATIVE METABOLISM IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

thematic review series

Chapter 26 Biochemistry 5th edition. phospholipids. Sphingolipids. Cholesterol. db=books&itool=toolbar

Liver biopsy as the gold standard for diagnosis. Pierre BEDOSSA

Fast-food, Fatty liver, & Insulin Resistance. Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna

Amelioration of nonalcoholic fatty liver disease by hepatic stimulator substance via preservation of carnitine palmitoyl transferase-1 activity

Lipid and Bile Acids as NAFLD- Related Biomarkers

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Progress in Lipid Research

Adipose tissue: Roles and function in diabetes and beyond. August 2015; SAGLB.DIA

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NAFLD & NASH: Russian perspective

Company Overview. September 2018 NASDAQ: MDGL

Bariatric Surgery and Liver Transplantation

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

Disclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH?

BCM 221 LECTURES OJEMEKELE O.

Metabolic Syndrome and HCC. Jacob George

Research Article Inhibition of Ceramide De Novo Synthesis Ameliorates Diet Induced Skeletal Muscles Insulin Resistance

Case Presentation. Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010

Role of Adipocytokines in the Induction of Experimental Non Alcoholic Fatty Liver Disease

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways

Integrating Multiple Data using Syngene s Virtual Liver

Extracellular vesicles and ceramide: new mediators for macrophage chemotaxis? Natalie J. Torok

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

DM, NAFLD, and conjugated linoleic acid (omega 6); what is the link

Sphingosine-1-phosphate signaling and cardiac fibrosis. Department of Physiology, Kanazawa University School of Medicine, Kanazawa, Japan

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

Liver Disease NASH/Fibrosis Model

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Repurposing Matrine for the Treatment. of Non-Alcoholic Fatty Liver Disease

EFFECTS OF VITAMIN D ON PRO-INFLAMMATORY CYTOKINES ASSOCIATED WITH THE PATHOGENESIS OF NON-ALCOHOLIC FATTY LIVER DISEASE NYPIAT MARTIN AYOUK, B.D.S.

Non-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research

The Role Of Crebh In Hepatic Energy Regulation Under Metabolic Stress

FGF21 Resistance in Adipose Tissues as a Cause of Insulin Resistance

DIAGNOSIS OF NASH LIVER BIOPSY. PHC

Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice

Oils Rich in alpha-linolenic acid independently protect against characteristics of fatty liver disease in the delta-6 desaturase null mouse

3-Thia Fatty Acids A New Generation of Functional Lipids?

(C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise 1 3

Widespread concern about the role of SFA in heart disease: Is it justified?

Most obese people develop fatty liver, which is

Phospholipids Metabolism

Molecular mechanisms involved in hepatic steatosis and insulin resistance

Metabolism of acylglycerols and sphingolipids. Martina Srbová

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

"Fatty acid dysregulation in NAFLD" Studying the fasting to fed state transition. Outline

Defective TNF-α mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice

Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis

Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences

Supplementary Figure 1

Yun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis

Division of Gastroenterology, Hepatology and Nutrition Research. Research. Matthew Cave, M.D. Cave Research. Cave Research

Circadian pathways as a mediator between alcohol and liver disease

Transcription:

Cholesterol and Sphingolipids in Non-Alcoholic fatty liver disease. José C. Fernández-Checa Liver Unit, Hospital Clinic CIBEK and IDIBAPS Instituto Investigaciones Biomédicas Barcelona Consejo Superior Investigaciones Científicas Barcelona, Spain ICDM 2013 & 5 thaasd Seoul, Nov 7 2013

NAFLD FATTY LIVER DISEASE Steatosis Steatohepatitis NASH Cirrhosis/HC ASH ALD

Inflammation Hepatocellular death Oxidative stress Fibrosis

?

Mechanisms involved in ALD/NAFLD Alcohol Methionine metab Homocysteine Acetaldehyde Obesity Insulin resistance Type 2 diabetes ALD NAFLD ER stress Mitochondrial dysfunction NASH: mitochondrial disease Disease progression

Mitochondrial Cholesterol in Steatohepatitis * Lombardi diet feeding (choline deficient) 2-14 days * * Ob/ob mice Ob/ob mice Triglyceride/FFA loading Cholesterol * loading TNF 2% cholesterol feeding (HC) NPC1 knockout mice TNF FFA GSH TNFR1/R2 endosomes GSH TNFR1/R2 ApoB + TG Susceptibility to TNF/Fas? ER Oil-Red ASH/NASH Filipin

Cholesterol loading sensitizes hepatocytes to TNF Mari et al, Cell Metab, 2006

Mitochondrial free cholesterol loading increases membrane order and depletes mgsh Mari et al, Cell Metab 2006

Impact of free cholesterol in human NASH?

Enhanced free cholesterol in human NASH. Caballero, J Hepatol, 2009

StARD1, a mitochondrial cholesterol carrier, is overexpressed in human NASH. # #. FC 11+/-3 13+/-4 52+/-6 (µg/mg protein) Caballero, J Hepatol, 2009

TNF/Fas 2-OGC GSH StARD1 CL GSH CLOOH GSH 2-OGC Susceptibility to TNF/Fas ASH/NASH

2-OGC GSH? StARD1? CL GSH CLOOH TNF/Fas GSH 2-OGC Susceptibility to TNF/Fas ASH/NASH

Mechanisms involved in ALD/NAFLD Alcohol Methionine metab Homocysteine Acetaldehyde Obesity Insulin resistance Type 2 diabetes ALD NAFLD ER stress? Mitochondrial cholesterol loading Disease progression

Tunicamycin-induced ER stress induces StARD1 expression which is prevented by TUDCA PMH + Tm StARD1 SREBP-2 Thus, StARD1 is a novel target gene regulated by ER stress Fernandez et al, 2012

Mechanisms involved in ALD/NAFLD Alcohol Methionine metab Homocysteine Acetaldehyde Obesity Insulin resistance Type 2 diabetes ALD NAFLD ER stress Lipogenesis Insulin resistance? Mitochondrial dysfunction Oxidative stress Cell death mchol, mgsh Disease progression

Ceramide generation in cells Serine+ Palmitoyl-CoA SPT 3-ketoesphinganine Sphinganine ER (de novo synthesis) Sphingosine Dihydroceramide CERAMIDE Pro-apoptotic Pro-fibrotic Pro-NAFLD ASMase NSMase ASMase Endosomes/lysosomes Sphingomyelin Garcia-Ruiz et al, J. Clin. Invest. 2003 Mari et al, J. Clin. Invest. 2004 Mari et al, Cell Metab 2006 Mari et al, Gastroenterology 2008 Moles et al, Hepatology 2010 Moles et al, Am J. Pathol 2011 Moles et al, J. Biol. Chem 2012 Fernandez et al, J Hepatol 2013 Fucho et al, Sci Transl Med 2013 Baulies et al, In prep 2013

EXPERIMENTAL DESIGN 1 HFD (60% cal) MCD OLESTEROL FILIPIN ASMase -/- mice 2 HFD (60% cal) + Amitriptyline SPHINGOMYELIN ASMase +/+ mice (WT mice)

ASMase is required for HFD or MCD-induced macrosteatosis Fucho et al, 2013

HFD MCD ASMase Steatosis ASMase is required for HFD and MCD induced steatosis

ASMase? HFD ER stress steatosis

ASMase deficiency prevents HFD-induced ER stress ATF4 PDI Edem Fucho et al, 2013

But ASMase KO mice is sensitive to tunicamycin-induced ER stress and steatosis Fernandez et al, 2013 Fucho et al, 2013

HFD ASMase ER stress ASMase is required for HFD induced ER stress Does ASMase directly induce ER stress?

ASMase induces ER stress and StARD1 upregulation via disruption of ER Ca 2+ homeostasis Fernandez et al, 2013

If cholesterol is not in mitochondria, where does cholesterol accumulate in ASMase null mice?

ASMase null mice exhibit lysosomal cholesterol accumulation Fucho et al, 2013

What is the impact of increased lysosomal cholesterol? Lysosomal membrane permeabilization (LMP) Lipotoxicity Cell death

ASMase null mice are resistant to LMP and palmitic acid-induced lipotoxicity Fucho et al, 2013

1. ASMase regulates lysosomal cholesterol homeostasis. 2. The deficiency in ASMase determines increased lysosomal cholesterol content which, in turn, decreases LMP.

EXPERIMENTAL DESIGN 1 HFD (60% cal) MCD ASMase -/- mice 2 HFD (60% cal) + Amitriptyline (an ASMase inhibitor) ASMase +/+ mice (WT mice) HFD 0 wk WT mice+hfd HFD+Ami 8 wk 16 wk

Amitriptyline inhibits HFD-induced obesity and glucose intolerance Fucho et al, 2013

Amitriptyline inhibits HFD-induced steatosis, liver damage, fibrosis and inflammation Fucho et al, 2013

SUMMARY 1. StARD1 expression and mitochondrial cholesterol loading are controlled by ER stress 2. ASMase is required for HFD-induced ER stress and steatosis 3. ASMase controls lysosomal cholesterol loading and lysosomal membrane permeabilization 4. ASMase inhibition by amitriptyline prevents HFD-induced obesity and glucose intolerance 5. ASMase targeting by amitriptyline rescues HFD-induced NASH.

ASMase as a novel target for NAFLD Alcohol Methionine metab Homocysteine Acetaldehyde Obesity Insulin resistance Type 2 diabetes ALD NAFLD ER stress Lipogenesis Insulin resistance ASMase Mitochondrial dysfunction Oxidative stress Cell death amitriptylline Lysosomal LMP Lipotoxicity Cell death Disease progression

Thank you!! Collaborations Gorka Basañez Bilbao, Spain Hide Tsukamoto Neil Kaplowitz Los Angeles, CA B.Karten, Nova Scotia, CA S. Zanlungo, Santiago Chile C. Trautwein Aachen, DE Grant Support: NIAAA, NIH, SAF, FIS, CiberEHD